Sana Biotechnology Inc (SANA) Stock Price, Quote & News

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modi...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 701 7914

Website: www.sana.com

Address:

188 East Blaine Street, Suite 400, Seattle, United States

JerryMalone32 Nov. 12 at 11:18 AM

$SANA did CTA ever come back?

0 · Reply

BriOnH Nov. 12 at 7:23 AM

$SANA November Presentation Stack https://ir.sana.com/static-files/608d978c-5acb-49aa-9f60-bce8d3575ff2

1 · Reply

Harold2029 Nov. 11 at 8:09 PM

$SANA an analyst is taking a chance at a 100x. So we’ve been digging…. Of their remedy for sustained insulin is successful this would be a tremendous benefit for the entire global population. … so yes, a 100x would be plausible.

0 · Reply

LoveRetailFroth Nov. 11 at 5:20 PM

$RXRX My 💎 s this $AMLX $SANA All bound for $30 plus 🚀🤑

0 · Reply

Harold2029 Nov. 11 at 5:17 PM

$ENGN …took profits to: $SANA a 100x …follow me …

1 · Reply

Raymond808 Nov. 11 at 4:17 AM

$SANA needs more buying power to $5 than we started short squeeze

0 · Reply

LoveRetailFroth Nov. 10 at 8:09 PM

$PLTR Yeah Tom Lee is right! Fund managers are behind & want the market to fall! Retail is way ahead of FMs ! $PLTY $RXRX $SANA

0 · Reply

Blizzy Nov. 10 at 6:27 PM

$SANA bought 100 shares in the Roth for “what if” lotto purposes

1 · Reply

LoveRetailFroth Nov. 10 at 2:50 PM

$RXRX Good Morning ☕️ $SANA $AMLX $PLTY

1 · Reply

LunarPixel87 Nov. 10 at 1:31 AM

$LCTX No, this all started because someone posted in $SANA about LCTX and I got a bunch of crap for asking honest questions about it. Sana isn't crap, you can look on reddit for some pretty good lengthy writeups (https://www.reddit.com/r/wallstreetbets/comments/1lkwgbi/sana_unequivocally_has_type_1_diabetes_cure_and/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button). They have about $170M cash right, runway for at least a year, they are reducing burn and prioritizing T1D. Current investors are committed to providing all capital needed to see T1D through (as stated by CEO). Their human data is mind-blowingly good and a massive competitive advantage, published in world's best journals. Their tech is TRANSPARENT. They have data and patents proving they have all the pieces working that are needed for a T1D cure. They will have a monopoly on this cure when it is approved and the market size will conservatively be $100B+. They are trading at a massive discount right now. You can whine about dilution all you want. It won't matter in the long run at the current price.

1 · Reply

Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D

Oct 16, 2025, 4:18 PM EDT - 26 days ago

Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight

Oct 15, 2025, 12:15 PM EDT - 27 days ago

Sana Biotech Stock — The Next '100-Bagger'?

Sep 8, 2025, 4:34 PM EDT - 2 months ago

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:42 AM EDT - 2 months ago

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 10:03 PM EDT - 2 months ago

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 2 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX IQV MRNA

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Sana Biotechnology to Present at September 2025 Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 2 months ago

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 8, 2025, 2:58 PM EDT - 3 months ago

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Aug 6, 2025, 11:24 PM EDT - 3 months ago

Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 4:38 PM EDT - 3 months ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

MCRB

Aug 4, 2025, 11:35 AM EDT - 3 months ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Jun 23, 2025, 10:05 AM EDT - 5 months ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jun 23, 2025, 7:39 AM EDT - 5 months ago

Two Biotech Stocks Poised For Big Moves On Monday

LCTX

Jun 9, 2025, 4:05 PM EDT - 5 months ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

May 28, 2025, 4:05 PM EDT - 5 months ago

Sana Biotechnology to Present at June 2025 Investor Conferences

May 19, 2025, 3:10 PM EDT - 6 months ago

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

May 19, 2025, 11:57 AM EDT - 6 months ago

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

May 14, 2025, 2:50 PM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 12, 2025, 4:05 PM EDT - 6 months ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 8, 2025, 5:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

Apr 19, 2025, 8:10 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Mar 24, 2025, 11:45 PM EDT - 8 months ago

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Mar 17, 2025, 4:05 PM EDT - 8 months ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 4:05 PM EST - 9 months ago

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

Jan 8, 2025, 4:05 PM EST - 10 months ago

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

JerryMalone32 Nov. 12 at 11:18 AM

$SANA did CTA ever come back?

0 · Reply

BriOnH Nov. 12 at 7:23 AM

$SANA November Presentation Stack https://ir.sana.com/static-files/608d978c-5acb-49aa-9f60-bce8d3575ff2

1 · Reply

Harold2029 Nov. 11 at 8:09 PM

0 · Reply

LoveRetailFroth Nov. 11 at 5:20 PM

$RXRX My 💎 s this $AMLX $SANA All bound for $30 plus 🚀🤑

0 · Reply

Harold2029 Nov. 11 at 5:17 PM

$ENGN …took profits to: $SANA a 100x …follow me …

1 · Reply

Raymond808 Nov. 11 at 4:17 AM

$SANA needs more buying power to $5 than we started short squeeze

0 · Reply

LoveRetailFroth Nov. 10 at 8:09 PM

$PLTR Yeah Tom Lee is right! Fund managers are behind & want the market to fall! Retail is way ahead of FMs ! $PLTY $RXRX $SANA

0 · Reply

Blizzy Nov. 10 at 6:27 PM

$SANA bought 100 shares in the Roth for “what if” lotto purposes

1 · Reply

LoveRetailFroth Nov. 10 at 2:50 PM

$RXRX Good Morning ☕️ $SANA $AMLX $PLTY

1 · Reply

LunarPixel87 Nov. 10 at 1:31 AM

1 · Reply

LunarPixel87 Nov. 9 at 10:18 PM

$LCTX $SANA the dosage size for OpRegen is several orders of magnitude smaller than that needed for islet cell therapy. I believe LCTX can do cGMP manufacturing. I don't believe LCTX has a uniquely superior scale up process. The cell numbers they are quoting doesn't support that argument.

0 · Reply

LunarPixel87 Nov. 9 at 10:08 PM

$LCTX $SANA Where are you getting the 10^9 billion claim from LCTX? Sept 8 press release clearly stated hundreds of millions cells. And again, we have no public details of LCTX's process. Who is the CDMO that Sana is using? Clearly not LCTX and whatever CDMO Sana chose must be suitable to scale Sana's islet for clinical trials or they wouldn't be working with them. This implies there exists other companies just as suitable, if not more suitable, as LCTX to scale cell manufacturing. If LCTX's process is so uniquely superior to other CDMOs, why is Sana not already partnering with them? If LCTX doesn't want to be a CDMO (this seems to be the case) and wants to make their own islet cell therapy, how are they going to get around all the IP needed to realize that that others own?

0 · Reply

DiligentInvesting Nov. 9 at 10:00 PM

$LCTX $SANA LCTX: Proven platform for analogous cell products, but no specific islet runs yet. In Q3 2025, completed full cGMP production runs for OpRegen (retinal cells) and OPC1 (oligodendrocytes) from the same VAC system, yielding viable clinical-grade cells and supporting "millions of doses." Islet program (launched Sep 2025) applies this directly, claiming feasibility for hundreds of millions of islet cells per dose, but remains in early development with no completed islet-specific runs announced. LCTX has stronger evidence of transferable, scalable cGMP manufacturing maturity, while SANA has clinical proof of islet function (via UP421) but unproven stem cell-derived scaling. Neither has fully proven commercial-scale islet production as of November 2025; both programs are advancing rapidly toward that goal.

1 · Reply

DiligentInvesting Nov. 9 at 9:59 PM

$LCTX $SANA SANA (SC451): No proven large-scale islet production. SC451 remains pre-clinical with a HIP-edited master cell bank ready for GMP, but manufacturing is outsourced to CDMOs. Clinical proof exists for precursor UP421 (HIP-modified primary islets from donors): transplanted without immunosuppression, showed survival, immune evasion, and insulin production (stable C-peptide, positive MMTT) up to 12 weeks (NEJM publication) and 6 months. However, UP421 uses limited donor islets (not scalable stem cell-derived), and SC451 has no reported production runs or doses manufactured at scale.

0 · Reply

DiligentInvesting Nov. 9 at 9:50 PM

$LCTX $SANA SANA: No fully proven large-scale production to date. While the Bothell facility opened in 2024 and supported early-stage process development, there are no public reports of completed cGMP runs for clinical doses or commercial validation. The 2025 pivot to CDMOs implies internal capabilities remain unproven at scale, with reliance on partners for any near-term output. LCTX: Proven cGMP production capabilities. In May 2025, LCTX announced successful completion of a full production run for two distinct product candidates (OpRegen for retinal disease and VAC-NC1 for neuronal support) using its cGMP cell banking system, yielding viable cells for clinical use. This was followed by initiating a Type 1 diabetes transplant program in Sep 2025, directly deploying these capabilities to produce islet-like cells at scale (addressing ~10^9 cells per patient). Q3 2025 earnings highlighted leveraging this for overcoming industry-scale challenges, confirming operational maturity.

2 · Reply

LunarPixel87 Nov. 9 at 9:08 PM

$LCTX Still waiting for someone to logically disprove my claim that LCTX does not have an advantage over others for producing islet cells. So far, I've gotten some insults (to be expected). I corrected a link. And some people seem to actually be taking me seriously. I am ultra long $SANA, don't care about LCTX at all and I think LCTX has 0 impact on Sana stock price. Not short or long LCTX. Worried for LCTX shareholders though. LCTX CEO is clearly making false claims and being secretive about their scale up process (which in the CEO's own words is WORSE than competitors). LCTX is giving me Theranos vibes.

1 · Reply

LunarPixel87 Nov. 9 at 9:02 PM

$LCTX $SANA [repost with correct 1st link] I found some actual math to back up how so full of crap $LCTX is. Mind you, this is from ~1 hour of simple research by an actual bioengineer. This article here (https://www.genengnews.com/gen-edge/lineage-cell-therapeutics-makes-medicines-based-on-transplanting-differentiated-cells/#:~:text=Cells%20behave%20differently%20based%20on,scale%20poses%20some%20daunting%20challenges.%E2%80%9D) states they can make 2500 courses of RPE product per 3L bioreactor. Per this link (https://investor.lineagecell.com/static-files/0a63d555-a7d6-44a0-8e11-d5d08f65754c) page 5, 1 course is either 50k or 200k cells. Multiply by 2500, that's 125 million to 500 million cells per 3L reactor. That's crap. This presentation (https://www.youtube.com/watch?v=AjSSFOkDG6U&t=1625s) @ 27:19 from lab of former Sana VP used a 3L bioreactor from PBS here https://www.pbsbiotech.com/products/pbs-3 (hey, unlike LCTX, you can actually see this company's tech!!!!! a simple fkn wheel that spins!) to make 3.3 billion islet cells. And in the LCTX press release (https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-initiates-cell-transplant-program-type), LCTX boasted about making hundreds of millions of islet cells, an order of magnitude less than the 3.3 billion Sana can already make and not even a full dose for T1D (~1 billion cells).

0 · Reply

LunarPixel87 Nov. 9 at 8:38 PM

$SANA $LCTX https://www.genengnews.com/gen-edge/lineage-cell-therapeutics-makes-medicines-based-on-transplanting-differentiated-cells/#:~:text=Cells%20behave%20differently%20based%20on,scale%20poses%20some%20daunting%20challenges.%E2%80%9D This is where I got the 2500 courses per 3L claim from. From the CEO of LCTX himself. I don't know why the links in my other posts are not correct. stocktwits is very finnicky sometimes. I could have sworn those links were correct. Not sure what happened.

0 · Reply

LunarPixel87 Nov. 9 at 8:24 PM

$LCTX $SANA I'm not pumping it. I genuinely believe it's undervalued and make a rational case for it rather than blindly saying it's good. Insulting me is not helpful. Knee jerk response when you know you're wrong. I presented the facts about LCTX, try and use facts to disprove me, not insults.

1 · Reply

LunarPixel87 Nov. 9 at 8:21 PM

$LCTX $SANA I'm not long or short LCTX, never said anything about Sana. Your response is just ignoring the facts I presented. Not helpful

0 · Reply

Forenzi Nov. 9 at 11:33 AM

$LCTX $SANA I just checked your posting history—-you’re the most constant annoying SANA pumper out there!!! I now see your motive for joking this thread! So laughable!

2 · Reply

Forenzi Nov. 9 at 11:27 AM

$LCTX $SANA you claim you’re not long but you never mention if you’re long SANA . I’m a bit leery of someone who’s never been a regular poster here that comes out of nowhere and trashes LCTX and insinuate they’re fooling people and you’re the only one that can decipher this to help us mere mortals from financial ruin!

0 · Reply

Market Cap	972.63M
Revenue (ttm)	0.00
Net Income (ttm)	-266.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,686,500
Avg Vol	4,962,688
Day's Range	N/A - N/A
Shares Out	237.81M
Stochastic %K	31%
Beta	1.94
Analysts	Strong Sell
Price Target	$8.57